Dry Eye Disease Clinical Trial Insight, Pipeline Assessment, Emerging Drugs | DelveInsight

Dry Eye Disease Clinical Trial Insight, Pipeline Assessment, Emerging Drugs | DelveInsight

Dry eye disease Pipeline Insight, 2020

DelveInsight launched a new report on “Dry eye disease Pipeline Insight, 2020”.

Dry eye disease Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Dry eye disease market. A detailed picture of the Dry eye disease pipeline landscape is provided, which includes the disease overview and Dry eye disease treatment guidelines. The assessment part of the report embraces in-depth Dry eye disease commercial assessment and clinical assessment of the Dry eye disease pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dry eye disease collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The launch of the emerging therapies is expected to significantly impact Dry Eye Disease treatment scenario in the upcoming years:-
Drugs covered

  1. OC‐01/OC‐02
  2. OCU 310
  3. HMB9036
  4. Visomitin
  5. RGN‐295
  6. Travilermide ophthalmic solution
  7. KPI‐121

And many others

The key players in Dry Eye Disease market are:

  1. Oyster Point Pharma
  2. Ocugen
  3. HanAI Biopharma
  4. Mitotech Pharma
  5. ReGen Tree
  6. Mimetogen Pharmaceuticals
  7. Kala Pharmaceuticals

And many others


Request for sample pages : https://delveinsight.com/sample-request/dry-eye-disease-pipeline-insight


Dry eye disease Analytical Perspective by DelveInsight

  • In-depth Dry eye disease Commercial Assessment of products 

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

  • Dry eye disease Clinical Assessment of products 

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.


Scope of the report

  • The Dry eye disease report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Dry eye disease across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Dry eye disease therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Dry eye disease research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Dry eye disease.


Report highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Dry eye disease.    
  • In the coming years, the Dry eye disease market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. 
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Dry eye disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Dry eye disease treatment market. Several potential therapies for Dry eye disease are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Dry eye disease market size in the coming years.  
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Dry eye disease) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. 


Request for sample pages : https://delveinsight.com/sample-request/dry-eye-disease-pipeline-insight


Key Questions

  • What are the current options for Dry eye disease treatment?
  • How many companies are developing therapies for the treatment of Dry eye disease
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Dry eye disease?
  • How many Dry eye disease emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Dry eye disease?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies? 
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Dry eye disease market? 
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Dry eye disease?  
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Dry eye disease therapies? 
  • What are the clinical studies going on for Dry eye disease and their status?
  • What are the results of the clinical studies and their safety and efficacy? 
  • What are the key designations that have been granted for the emerging therapies for Dry eye disease
  • How many patents are granted and pending for the emerging therapies for the treatment of Dry eye disease



Related Reports:

Dry Eye Disease (DED) – Market Insight, Epidemiology and Market Forecast – 2028

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Dry Eye Disease (DED) from 2017 to 2028 segmented by seven major markets.

Dry eye disease – Epidemiology Forecast to 2030

The Dry eye disease epidemiology covered in the report provides historical as well as forecasted Dry eye disease epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.


Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/